You are here

P&T® Journal contents for June 2005


Health Care & Law
Dr. Field discusses the trend of states allowing psychologists to prescribe psychotropic medications.
Robert I. Field, JD, MPH, PhD
Book Review
Author: Debra Niehoff, PhD
Reviewed by Mark Noble, PhD
The authors compare the efficacy of three antiemetic medications for PONV: ondansetron (Zofran®), granisetron (Kytril®), and dolasetron (Anzemet®).
Shan Wang, PharmD, Joseph Greco, MD, Reena A. Joseph, PharmD Candidate, Martin Feuerman, MS, and Brian Malone, MS
The authors continue their discussion of pharmacological and nonpharmacological therapies with a focus on criteria for the best agent, the subtypes of breakthrough pain, and the economic and quality-of life considerations.
Daniel Bennett, MD, Allen W. Burton, MD, Scott Fishman, MD, Barry Fortner, PhD, Bill McCarberg, MD, Chris Miaskowski, PhD, RN, David Nash, MD, MBA, Marco Pappagallo, MD, Richard Payne, MD, James Ray, PharmD, Eugene R. Viscusi, MD, and Winston Wong, PharmD


David Nash, MD, MBA, describes the mission and vision of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR) upon the occasion of its 10th anniversary.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses some common and dangerous problems associated with the dosing of epinephrine and other drugs used for resuscitating patients.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas comments on the refusal of the Centers for Medicare & Medicaid Services to fund pharmacy residents in their second year of training.
Stephen Barlas
Drug Forecast
The authors review the benefits of ezetimibe/simvastatin (Vytorin®) as a therapeutic approach for hyperlipidemia.
Katrina Touchstone, PharmD Candidate, Laura Stark, PharmD Candidate, Marlon Honeywell, PharmD, Marvin Scott, PharmD, and Evans Branch III, PharmD
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.